InsiderSignal.AI

InsiderSignal.ai

ZBIO - Zenas Biopharma, Inc.

Insider Purchase by Sr One Capital Management, LLC (10%)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

4 months ago, Sr One Capital Management, LLC, serving as 10% owner at Zenas Biopharma, Inc. (ZBIO), purchased 126,315 shares at $19.00 per share, for a total transaction value of $2,399,985.00. Following this transaction, Sr One Capital Management, LLC now holds 5,037,854 shares of ZBIO.

This purchase represents a 3.00% increase in Sr One Capital Management, LLC's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, October 9, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, October 14, 2025, 5 days after the trade was made.

Zenas Biopharma, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Sr One Capital Management, LLC

10%

SR One Capital Management, LLC is a transatlantic biotechnology venture capital firm founded in 2020, specializing in partnering with founders and entrepreneurs to translate innovative science into medicines through a 'back-and-build' investment approach.[[1]](https://www.srone.com)[[4]](https://www.privateequityinternational.com/institution-profiles/sr-one.html) Headquartered with offices in key biotech hubs including Wayne (as per filings), Redwood City on the US West Coast, and London, UK, the firm focuses on companies with strong fundamentals, clear development pathways, and novel disease treatments, providing strategic support via its geographic reach.[[1]](https://www.srone.com)[[2]](https://whalewisdom.com/filer/sr-one-capital-management-lp)[[4]](https://www.privateequityinternational.com/institution-profiles/sr-one.html) As of June 30, 2025, SR One manages approximately $461 million in discretionary assets across 17 clients, with top holdings including Arcellx Inc (33.49%), ARS Pharmaceuticals (15.18%), CRISPR Therapeutics (11.06%), and Zenas BioPharma, Inc. (ZBIO) at 10.32% of its portfolio, positioning it as a 10% owner and active corporate insider in recent trades.[[2]](https://whalewisdom.com/filer/sr-one-capital-management-lp)[[3]](https://www.gurufocus.com/insider/178256/sr-one-capital-management,-llc) Leadership includes partners like Jake Nunn in Redwood City and venture partners such as Eliot Charles in London, supported by roles in finance, legal, and compliance; the firm has raised multiple funds since inception, with 3 funds currently in market and 6 closed.[[4]](https://www.privateequityinternational.com/institution-profiles/sr-one.html)

View full insider profile →

Trade Price

$19.00

Quantity

126,315

Total Value

$2,399,985.00

Shares Owned

5,037,854

Trade Date

Thursday, October 9, 2025

136 days ago

SEC Filing Date

Tuesday, October 14, 2025

Filed 5 days after trade

HEALTHCAREBIOTECHNOLOGY

About Zenas Biopharma, Inc.

Company Overview

No company information available
View news mentioning ZBIO

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/764221

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime